Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study

Jonathan J. Morrison, MB ChB, MRCS; Joseph J. Dubose, MD; Todd E. Rasmussen, MD; Mark J. Midwinter, BMedSci, MD, FRCS

Objectives: To characterize contemporary use of tranexamic acid (TXA) in combat injury and to assess the effect of its administration on total blood product use, thromboembolic complications, and mortality.

Design: Retrospective observational study comparing TXA administration with no TXA in patients receiving at least 1 unit of packed red blood cells. A subgroup of patients receiving massive transfusion (≥10 units of packed red blood cells) was also examined. Univariate and multivariate regression analyses were used to identify parameters associated with survival. Kaplan-Meier life tables were used to report survival.

Setting: A Role 3 Echelon surgical hospital in southern Afghanistan.

Patients: A total of 896 consecutive admissions with combat injury, of which 293 received TXA, were identified from prospectively collected UK and US trauma registries.

Main Outcome Measures: Mortality at 24 hours, 48 hours, and 30 days as well as the influence of TXA administration on postoperative coagulopathy and the rate of thromboembolic complications.

Results: The TXA group had lower unadjusted mortality than the no-TXA group (17.4% vs 23.9%, respectively; \( P = .03 \)) despite being more severely injured (mean [SD] Injury Severity Score, 25.2 [16.6] vs 22.5 [18.5], respectively; \( P < .001 \)). This benefit was greatest in the group of patients who received massive transfusion (14.4% vs 28.1%, respectively; \( P = .004 \)), where TXA was also independently associated with survival (odds ratio=7.228; 95% CI, 3.016-17.322) and less coagulopathy (\( P = .003 \)).

Conclusions: The use of TXA with blood component–based resuscitation following combat injury results in improved measures of coagulopathy and survival, a benefit that is most prominent in patients requiring massive transfusion. Treatment with TXA should be implemented into clinical practice as part of a resuscitation strategy following severe wartime injury and hemorrhage.

ARCH SURG/VOL 147 (NO. 2), FEB 2012 WWW.ARCHSURG.COM

©2012 American Medical Association. All rights reserved.

See Invited Critique at end of article

VASCULAR DISRUPTION WITH concomitant hemorrhage is a leading cause of death in civilian and military trauma.1,2 Experience from the wars in Iraq and Afghanistan has led to advances in resuscitation for hemorrhagic shock, with identification of optimum ratios of blood components to be used in this setting.3,4 These new strategies are based on early and balanced administration of packed red blood cells (PRBCs), fresh frozen plasma (FFP), platelets, and cryoprecipitate to restore circulating volume and clotting factors.6 Despite these advances, the effectiveness of a medication to improve mortality in the setting of hemorrhagic shock has not been established.

The CRASH-2 trial demonstrated that the antifibrinolytic agent tranexamic acid (TXA) resulted in reduced mortality following civilian trauma.7 Tranexamic acid is a lysine analog that occupies binding sites on the plasminogen molecule, inhibiting fibrinolysis. It has an established safety and efficacy profile,8-12 and its primary effect of inhibition of clot breakdown portends a favorable effect on patients with hemorrhage from vascular disruption.7,13 Because plasmin is known to have proinflammatory effects, other beneficial effects have been suggested.14,15 Despite their value, the CRASH-2 results are not fully applicable to wartime injury as the study was performed in civilian hospitals, many of which lacked modern trauma and resuscitation practices. In addition, they provide no information on measures of coagulopathy or injury severity, and the mechanism of injury was mostly blunt rather than penetrat-
The use of TXA in the management of severe combat injury. The UK Defence Medical Service has used TXA since 2009 as part of a massive transfusion protocol, and the US Combat Casualty Care program has deferred use altogether. The objectives of this study are to report the experience of the use of TXA in the combat setting and to characterize its effect on measures of coagulopathy and survival following wartime injury.

METHODS

DESIGN AND STUDY GROUPS

A retrospective cohort study was performed with patients having been treated at a single surgical hospital at Camp Bastion, southern Afghanistan. Approval for the MATTERs Study was established through the UK Joint Medical Command Research Pillar and the US Army’s Medical Research and Material Command. From January 1, 2009, through December 31, 2010, consecutive patients who received at least 1 unit of PRBCs within 24 hours of admission following combat-related injury were identified using the UK Joint Theatre Trauma Registry. This included all coalition military personnel (designated North Atlantic Treaty Organization [NATO] military) and Afghan police, military, and civilians (designated host nationals) (Table 1). Information on US troops treated at this facility during this time was cross-referenced using the US Joint Theater Trauma Registry. Patients, regardless of designation, were required to have stable physiology prior to discharge. In the case of NATO military, this required stabilization for aeromedical evacuation; host nationals remained until they were clinically ready to be transferred to an Afghan national medical facility or to home.

Prior to 2010, TXA was administered at the discretion of the surgeon or anesthetist on the basis of clinical judgment and, in some instances, following demonstration of hyperfibrinolysis on rotational thromboelastography. Thereafter, as part of a major hemorrhage protocol or clinical practice guideline, TXA was administered to patients requiring emergency blood products or patients with evidence of hyperfibrinolysis. A standard dosing regimen consisted of an intravenous bolus of 1 g, repeated as felt indicated by the managing clinician. Patients who received TXA were assigned to the treatment group (TXA group) and compared with those who did not receive TXA (no-TXA group). Patients who received 10 or more units of PRBCs within 24 hours of admission following combat-related injury were identified using the UK Joint Theatre Trauma Registry.

The UK Defence Medical Service has used TXA since 2009 as part of a massive transfusion protocol, and the US Combat Casualty Care program has deferred use altogether. The objectives of this study are to report the experience of the use of TXA in the combat setting and to characterize its effect on measures of coagulopathy and survival following wartime injury.

Table 1. Demographic Data, Mechanism of Injury, Injury Severity, Physiology, and Transfusion Requirement for Overall and Massive Transfusion Groups

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall (N=896)</th>
<th>Massive Transfusion (n=231)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TXA (n=293)</td>
<td>No TXA (n=603)</td>
<td>P Valuea</td>
</tr>
<tr>
<td>TXA (n=125)</td>
<td>No TXA (n=196)</td>
<td>P Valuea</td>
</tr>
<tr>
<td>Demographic data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td>24.9 (9.6)</td>
<td>23.1 (10.1)</td>
</tr>
<tr>
<td>Male, %</td>
<td>97.3</td>
<td>94.2</td>
</tr>
<tr>
<td>Host national, No. (%)</td>
<td>116 (39.6)</td>
<td>261 (43.3)</td>
</tr>
<tr>
<td>NATO military</td>
<td>177 (60.4)</td>
<td>342 (56.7)</td>
</tr>
<tr>
<td>Mechanism of injury, %</td>
<td>25.3</td>
<td>36.7</td>
</tr>
<tr>
<td>GSW</td>
<td>74.7</td>
<td>62.4</td>
</tr>
<tr>
<td>Injury severity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISS, mean (SD)</td>
<td>25.2 (16.6)</td>
<td>22.5 (18.5)</td>
</tr>
<tr>
<td>AIS score $\geq$ 3, %</td>
<td>98.4</td>
<td>96.9</td>
</tr>
<tr>
<td>AIS score $\geq$ 8</td>
<td>68.0</td>
<td>51.0</td>
</tr>
<tr>
<td>Admission physiology, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCS score $\geq$ 8</td>
<td>63.3</td>
<td>35.6</td>
</tr>
<tr>
<td>SBP $\leq$ 90 mm Hg</td>
<td>22.8</td>
<td>13.8</td>
</tr>
<tr>
<td>PRBCs</td>
<td>11.8</td>
<td>9.8</td>
</tr>
<tr>
<td>FFP</td>
<td>10.3</td>
<td>8.6</td>
</tr>
<tr>
<td>Platelets</td>
<td>1.6</td>
<td>1.4</td>
</tr>
<tr>
<td>Cryoprecipitate</td>
<td>1.6</td>
<td>0.5</td>
</tr>
<tr>
<td>Time in ED, mean (SD), min</td>
<td>36 (25)</td>
<td>56 (55)</td>
</tr>
<tr>
<td>Lowest body temperature, mean (SD), °C</td>
<td>36.1 (1.1)</td>
<td>36.4 (0.9)</td>
</tr>
<tr>
<td>Pulmonary embolism, No. (%)</td>
<td>8 (2.7)</td>
<td>2 (0.3)</td>
</tr>
<tr>
<td>Deep venous thrombosis, No. (%)</td>
<td>7 (2.4)</td>
<td>1 (0.2)</td>
</tr>
</tbody>
</table>

Abbreviations: AIS, Abbreviated Injury Scale; ED, emergency department; FFP, fresh frozen plasma; GCS, Glasgow Coma Scale; GSW, gunshot wound; ISS, Injury Severity Score; NATO, North Atlantic Treaty Organization; OR, operating room; PRBCs, packed red blood cells; RTS, Revised Trauma Score; SBP, systolic blood pressure; TXA, tranexamic acid.

aStatistically significant values ($P < .05$) are bold.
24 hours were identified as the massive transfusion (MT) cohort and assigned to treatment (TXAMT) and nontreatment (no-TXA) groups (Figure 1).

END POINTS

Primary end points were 24 and 48 hours and in-hospital mortality. In-hospital mortality for US and UK patients included that which occurred within 30 days either at the hospital in Afghanistan or at any point throughout the aeromedical evacuation chain. For non-US and non-UK patients, in-hospital mortality included that which occurred within 30 days of being admitted to the surgical facility in Afghanistan. Secondary end points included transfusion requirements and coagulation parameters (prothrombin time and activated partial thromboplastin time). Determination of coagulopathy using these measures was made at 2 points: (1) admission to the emergency department of the surgical hospital; and (2) admission to the intensive care unit following the initial operation. Hypocoagulopathy was defined as a prothrombin time longer than 1.5 times the midpoint of normal (>18 seconds) or as an activated partial thromboplastin time greater than 1.5 times the normal range (>55 seconds). Additional end points included TXA dose and timing as well as the incidence of thrombotic events such as deep venous thrombosis (DVT) or pulmonary thromboembolism (PTE).

Data collected included demographic characteristics, admission physiology, treatment timelines, and 24-hour transfusion requirement (PRBCs, FFP, platelets, and cryoprecipitate). The Glasgow Coma Scale (GCS) score, systolic blood pressure (SBP), and respiratory rate at admission were used to generate a Revised Trauma Score, which is inversely related to trauma mortality. The Abbreviated Injury Scale (AIS) was used to report the anatomical injury pattern for 4 body regions (head, chest, abdomen, and extremity) and to calculate the Injury Severity Score (ISS) at admission (on a scale of 1-75). The following definitions were established: hypotension as an SBP of 90 mm Hg or lower; a significantly reduced conscious level as a GCS score of 8 or lower; and severe injury as an AIS score of 3 or higher.

STATISTICAL ANALYSIS

Comparison between the TXA and no-TXA groups was performed using a chi-squared test, and differences in means were assessed using t test or Mann-Whitney rank sum test. Continuous variables were dichotomized using defined cutoff values recorded at the time of admission: GCS score (≤8 vs >8), SBP (≤90 vs >90 mm Hg), ISS (≥15 vs ≤15), and body region AIS scores (≥3 vs <3). The following parameters were analyzed with univariate analysis for inhospital mortality: sex, nation status, mechanism of injury, ISS higher than 15, GCS score of 8 or lower at admission, SBP of 90 or lower at admission, body region AIS scores of 3 or higher, time in the emergency department (in minutes), time in the operating room (in minutes), hypocoagulopathy on admission, lowest body temperature (in degrees Celsius), and TXA administration. Factors achieving significance (P < .15) were entered into a multivariate, stepwise logistic regression analysis to identify those independently associated with mortality. To assess risk of DVT and PTE, a similar analysis was performed to determine the relation of the previously listed factors with this diagnosis. Adjusted odds ratios with 95% confidence intervals were derived from logistic regression and significance was set at P < .05 after adjustment for risk factors.

Follow-up (in days) was calculated and based on the time from the date of injury to the date of the last hospital record or 30 days, whichever was longest. Mantel-Cox log-rank test and Kaplan-Meier life table analysis was used to report survival in the treatment and nontreatment groups in the overall (TXA vs no-TXA) and MT (TXAMT vs no-TXAMT) cohorts.

RESULTS

DEMOGRAPHIC CHARACTERISTICS

Eight hundred ninety-six patients constituted the overall MATTERS Study cohort. Of these, 293 (32.7%) received intravenous administration of TXA (mean [SD] dose, 2.3 [1.3] g) within 1 hour of injury. Table 1 demonstrates the demographic characteristics, mechanism and severity of injury, and physiological and pathological end points of the overall and MT cohorts. There was a similar distribution of NATO military and host national patients among the TXA and no-TXA groups of the overall and MT cohorts. In the overall cohort, the TXA group had a higher ISS and a higher percentage of patients with severe extremity injury (Table 1). Additionally, the TXA group had a lower Revised Trauma Score and a greater percentage of patients presenting with a depressed GCS score and hypotension. The difference in injury severity was not as marked in the MT cohort, although the TXAMT group had a greater percentage of patients with severe extremity injury as well as a greater proportion of patients with a depressed GCS score than the no-TXAMT group.

Transfusion requirements in the overall cohort were higher for the TXA group compared with the no-TXA group (Table 1). The PRBC:FFP ratio in the TXA and no-TXA groups was the same (1:0.87 and 1:0.88, respectively). In the MT cohort, requirements were the same between the TXAMT and no-TXAMT groups with the exception of cryoprecipitate. The PRBC:FFP ratio in the TXAMT and no-TXAMT groups was the same (1:0.88 and 1:0.87, respectively). In the overall cohort, the rate of PTE and DVT were greater in the TXA group compared with the no-TXA group. This trend was similar in the MT cohort, where the TXAMT group had a higher rate of PTE compared with the no-TXAMT group. There were no fatalities attributed to PTE in either cohort.

HYPOCOAGULOPATHY AND MORTALITY

Figure 2 illustrates the percentage of patients considered hypocoagulopathic on admission to the emergency department and intensive care unit following operation. In both the overall and MT cohorts, there was a de-
increase in the percentage of patients in the TXA groups with hypocoagulopathy between these 2 points. Table 2 illustrates mortality in the 2 cohorts. In the overall cohort, the absolute reduction in in-hospital mortality for the TXA group was 6.5%, while the absolute reduction in mortality for the overall cohort and the groups that received massive transfusion. TXA indicates tranexamic acid.

Table 2 illustrates findings from the multivariate logistic regression analysis of factors having met model inclusion criteria ($P = .15$). As illustrated, in the overall cohort, a GCS score of 8 or lower, hypotension, and the presence of coagulopathy were independently associated with mortality. In the MT group, a GCS score of 8 or lower and an ISS of 15 or higher were associated with mortality, while TXA use was independently associated with survival. In a separate analysis, none of the clinical parameters had an association with DVT or PTE in either the overall or MT cohort. As such, no parameters, including administration of TXA, were associated with DVT or PTE.

Table 3. All-Cause Mortality of Overall and Massive Transfusion Groups Within 24 Hours, Within 48 Hours, and In-Hospital Mortality

<table>
<thead>
<tr>
<th>End Point</th>
<th>TXA</th>
<th>No TXA</th>
<th>$P$ Value$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;24 h</td>
<td>293 (9.6)</td>
<td>603 (12.4)</td>
<td>.20</td>
</tr>
<tr>
<td>&lt;48 h</td>
<td>264 (11.3)</td>
<td>507 (18.9)</td>
<td>.004</td>
</tr>
<tr>
<td>In-hospital mortality$^b$</td>
<td>264 (17.4)</td>
<td>603 (23.9)</td>
<td>.03</td>
</tr>
<tr>
<td>Massive transfusion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;24 h</td>
<td>125 (9.6)</td>
<td>196 (14.8)</td>
<td>.17</td>
</tr>
<tr>
<td>&lt;48 h</td>
<td>112 (10.4)</td>
<td>160 (23.5)</td>
<td>.003</td>
</tr>
<tr>
<td>In-hospital mortality$^c$</td>
<td>125 (14.4)</td>
<td>196 (28.1)</td>
<td>.004</td>
</tr>
</tbody>
</table>

Abbreviation: TXA, tranexamic acid.

$^a$Mean (SD) follow-up, 15 (13) days.

$^b$Statistically significant values ($P < .05$) are bold.

$^c$Statistically significant values ($P < .05$) are bold.

Figure 2. Percentage of patients with hypocoagulopathy on admission to the emergency department (ED) and then to the intensive care unit (ICU) following the initial operation. Coagulation data were available for 462 patients in the overall cohort and 155 patients in the groups that received massive transfusion. TXA indicates tranexamic acid.

Figure 3. Kaplan-Meier survival curve of the overall cohort, including patients receiving tranexamic acid (TXA) vs no TXA. $P = .006$, Mantel-Cox log-rank test.
Figure 4 illustrates survival curves for both groups from the MT cohort. The TXA MT group had superior 30-day survival compared with the no-TXA MT group (P = .004).

To our knowledge, the MATTERs Study is the first to examine the effectiveness of TXA in the management of wartime injury. Findings show that TXA improves markers of coagulation and results in lower mortality. The observation of improved survival confirms findings from the CRASH-2 trial and extends them to a population of patients with wartime injuries. The measures of injury severity and physiology in our study were not available in the CRASH-2 trial but now provide insight into which patients may benefit most from TXA. Findings suggest that the beneficial effect of TXA is more prominent in those with higher injury severity. Additionally, laboratory values not reported in the CRASH-2 trial afford new insight into the effect of TXA after trauma. The timing and magnitude of survival benefit of TXA should be taken in the context of a higher injury burden.

The mortality advantage shown with TXA in the CRASH-2 trial was subtle (absolute reduction of 1.5%); however, not all patients in that study were severely injured. For example, only half received a transfusion or required an operation. The 6.5% absolute reduction in mortality in our study in which all patients required a blood transfusion and an operation suggests a more significant benefit in those more severely injured. In light of these findings, it is tempting to speculate that the modest injury profile of the CRASH-2 cohort introduced a conservative bias against the TXA effect. This proposition is supported by observations from our study that show the effect to be greatest (absolute reduction of 13.7%) in the MT group. To place this in context, the number of patients required to be treated with TXA to achieve a mortality benefit of 1 was 67 in the CRASH-2 trial. Findings from our study in a more severely injured cohort suggest that as few as 7 patients need to be treated to provide that same benefit.

Measurements of coagulation in our study provide new insight into the effect ofTXA after trauma. The observation that TXA resulted in an improved coagulation profile supports the clot-stabilizing effect of this medication (Figure 2). It is worth noting that the TXA and no-TXA groups in both the overall and MT cohorts received similar, blood component–based resuscitation (Table I). The PRBC:FFP ratio in each of the groups is the same, indicating that the improvement in coagulopathy was the result of something other than different use of blood products. These findings also suggest that the increased transfusion requirements in the TXA groups were more related to severity of injury and not to worsening coagulopathy. The observation of the improved coagulation profile corroborates the CRASH-2 findings, which demonstrated reduced mortality from hemorrhage.

The timing and magnitude of survival benefit of TXA in the MATTERs Study suggests that a beneficial mechanism other than hemostasis may be present. Specifically, there is no difference in mortality between the TXA and no-TXA groups until the 48-hour point, a time at which bleeding is less likely to be the primary cause of death. Although hemostasis is important at and beyond 24 hours, it is also possible that attenuation of the inflammatory response plays a role in the survival benefit associated with TXA. In a study of TXA in cardiac surgery, Jimenez et al15 reported that the drug was independently associated with a reduced inflammatory response. The prospective randomized arm of the study was terminated early because of the marked benefit observed with TXA in reducing not only the inflammatory response but also rates of shock and ventilatory support. As one of several studies that have shown reduced bleeding and transfusion requirements with TXA in cardiac surgery,21-23 Casati et al23 reported lower postoperative levels of D-dimer and interleukin 6 with use of the drug. Several of these studies emphasize the interconnected nature of the fibrinolytic and inflammatory pathways, noting the potential benefit of inhibiting not just acute fibrinolysis but also secondary fibrinolysis as a means to reduce systemic inflammation.

The higher rate of DVT and PTE in the TXA group should be taken in the context of a higher injury burden, which is associated with thrombotic events.24-27 The number of venous thrombotic events in this study is too small to assess any independent risk of TXA; however, in light of the evidence of correction of hypocoagulability, it is plausible that the higher rates of thrombotic events relate to the TXA. Conversely, the increased rate of these events may reflect a survivorship phenomenon in the TXA group that has a relative risk reduction of mortality of 27% in the overall cohort and 49% in the MT cohort.

As a retrospective analysis of the trauma registries of the US and UK militaries, this study has a number of limitations worth noting. Because the clinical practice guideline, which included TXA use, was not introduced until the later part of the study period, there is the possibility that slight variations in the indications for use and dosing of the medication occurred. However, because this study reflects TXA use at 1 surgical facility during 24 consecutive months, it is unlikely that its use varied significantly throughout the period.
The retrospective nature of this study prevents in-depth understanding of the incidence of venous thrombotic events. Specifically, the incidence of these events was quantified using diagnostic codes to query each of the trauma registries. This method did not provide insight on the method used to screen for or diagnose these events or quantify in detail their clinical significance. Better knowledge of any association of TXA with venous thrombotic events will require a prospective study with these clinical end points in mind.

As this was a retrospective analysis, the exact cause or time of death was not able to be discerned in those who died. It is therefore likely that some patients who died very early in the course of their admission are included in the study cohort. Such patients are less likely to be affected by any therapeutic intervention such as TXA and thus risk introducing an immediate mortality bias. However, as there was no difference in mortality rates between cohorts at the 24-hour period, it is likely that such patients who died very early in their course were evenly distributed across the groups.

Finally, inclusion of host national patients limits the ability of this study to ascertain 30-day outcome information as most of these patients are discharged before this period. As all patients were discharged only when physiologically stable as a matter of safe and ethical care, we are confident that there is no hidden cohort of mortality after censoring. Additionally, the proportion of host national patients to NATO military patients was equally distributed across all of the study arms, making any bias related to patient demographic characteristics unlikely.

In conclusion, findings from the MATTERs Study demonstrate that the use of TXA in conjunction with a blood component–based resuscitation following combat injury results in improved measures of coagulopathy and survival. This benefit is present in all who receive blood transfusions in this setting but is most prominent in those requiring MT. This benefit is present in all who receive blood transfusions in this setting but is most prominent in those requiring MT. On the basis of these findings, early administration of TXA following severe wartime vascular disruption with hemorrhage should be implemented into clinical practice.

Accepted for Publication: July 18, 2011.
Published Online: October 17, 2011. doi:10.1001/archsurg.2011.287

Correspondence: Todd E. Rasmussen, MD, United States Air Force Medical Corps Deputy Commander, US Army Institute of Surgical Research, 3400 Rawley E. Chambers Ave, Ste B, Fort Sam Houston, TX 78234-6315 (todd.rasmussen@amedd.army.mil).

Author Contributions: Study concept and design: Morrison, Dubose, Rasmussen, and Midwinter. Acquisition of data: Morrison, Dubose, Rasmussen, and Midwinter. Analysis and interpretation of data: Morrison, Dubose, Rasmussen, and Midwinter. Drafting of the manuscript: Morrison, Dubose, Rasmussen, and Midwinter. Critical revision of the manuscript for important intellectual content: Morrison, Dubose, Rasmussen, and Midwinter. Statistical analysis: Morrison, Dubose, Rasmussen, and Midwinter. Administrative, technical, and material support: Morrison, Dubose, Rasmussen, and Midwinter. Study supervision: Dubose, Rasmussen, and Midwinter. Financial Disclosure: None reported.

Funding/Support: This work was supported by the Office of the US Air Force Surgeon General and was created in the performance of a contract with the Air Force Medical Support Agency.

Disclaimer: The viewpoints expressed in this article are those of the authors and do not reflect the official position of the US Department of Defense or the UK Defence Medical Service.

Previous Presentations: This paper was presented at the SWAN XIX Trauma Conference of the South West Australian Trauma Network; July 29, 2011; Sydney, Australia; and at the Advanced Technology Applications for Combat Casualty Care 2011 Conference of the Combat Casualty Care Research Program; August 16, 2011; Fort Lauderdale, Florida.

Additional Contributions: We are grateful to the staff at the UK Joint Theatre Trauma Registry (Academic Department of Military Emergency Medicine, Royal Centre for Defence Medicine, Birmingham) and US Joint Theatre Trauma Registry (US Army Institute of Surgical Research, Fort Sam Houston, San Antonio) for providing the data required for this study.

REFERENCES

17. Development, Concepts and Doctrine Centre. Transfusion medicine leaflet 2-24-1:
management of massive haemorrhage on operations. In: Joint Service Publica-

18. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guide-


22. Diprose P, Herbertson MJ, D'Shaughnessy D, Deakin CD, Gill RS. Reducing al-

23. Casati V, Della Valle P, Benussi S, et al. Effects of tranexamic acid on postop-

24. Adams RC, Hamrick M, Berenguer C, Senkowski C, Ochsnler MG. Four years of an aggressive prophylaxis and screening protocol for venous thromboamo-


ONLINE FIRST

Antifibrinolytics in Trauma Patients

Does It MATTER?

Our understanding of the coagulation system de-

fects associated with injury continues to evolve. Hy-

perfibrinolysis has been identified as one of 

these coagulation abnormalities. Recently, the therapeu-

tic impact of the antifibrinolytic tranexamic acid was ex-

amined in the CRASH-2 study. Despite a subtle but sig-

nificant outcome benefit, direct application of these results 

to clinical practice was made challenging by several fac-

ors, including the inclusion criteria that effectively di-

luted out those patients who were actually bleeding. These 

results became even more difficult to interpret when an 

analysis of the time from injury to treatment demon-

strated an increase in the risk of death due to bleeding if 

the antifibrinolytic was administered beyond 3 hours.

The MATTERS Study, however, specifically targeted 

the cohort of patients who were actively bleeding and de-

monstrated a strong association with improved survival. 

It is a retrospective study and as such does have its lim-

itations. Its data predate and cross over the CRASH-2 re-

lease date, highlighting the lack of standardized indica-

tions and dosing used throughout the study period. Like 

the studies before it, the MATTERS Study also failed to 

quantitate the degree of hyperfibrinolysis or its re-

sponse to treatment. In addition, a detailed analysis of 

the timing of treatment, a critical factor emphasized by 

the CRASH-2 trial, could not be performed.

And yet, when put into the context of the early mort-

ality benefit and neutral risk profile demonstrated in the 

CRASH-2 trial, the MATTERS Study provides even fur-

ther evidence that in trauma patients who are bleeding, 

tranexamic acid may be beneficial. Thus, the mecha-

nism of action, role of point-of-care tests in directing treat-

ment, dosing, and optimal timing all warrant further in-

vestigation.

This work is an important contribution to our under-

standing of coagulopathy in trauma. The authors should be 

congratulated for setting up a registry that allowed for 
data capture under such austere operating conditions and for 

analyzing their experience. Their commitment to the 

care of the injured soldier and the advancement of science 

stands as an example to us all.

Kenji Inaba, MD

Published Online: October 17, 2011. doi:10.1001 

/archsurg.2011.286

Author Affiliation: Division of Trauma and Surgical Critical 

Care, University of Southern California, LAC + USC 

Medical Center, Los Angeles.

Correspondence: Dr Inaba, Division of Trauma and Sur-

gical Critical Care, University of Southern California, 

LAC + USC Medical Center, 1200 N State St IPT, C5L100, 

Los Angeles, CA 90033 (kinaba@surgery.usc.edu).

Financial Disclosure: None reported.


2. Roberts I, Shakur H, Alola A, et al; CRASH-2 Collaborators. The impor-
